Reuters logo
La Jolla's low blood pressure treatment clears key study
2017年2月27日 / 上午11点07分 / 9 个月前

La Jolla's low blood pressure treatment clears key study

Feb 27 (Reuters) - La Jolla Pharmaceutical Co said its lead experimental drug to treat low blood pressure met the main goal of a late-stage study on patients with distributive shock who have not adequately responded to existing treatments.

Distributive shock is a state in which the heart is pumping well enough, but the blood is not distributed properly to the vital organs leading to severe hypotention.

The drug, LJPC-501, is La Jolla’s formulation of a natural peptide that regulates blood pressure. (Reporting by Natalie Grover in Bengaluru; Editing by Savio D‘Souza)

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below